Director Michael Purcell Buys $50K in Stock at 30x Current Market Price, Joining Insider Cluster

summarizeSummary

Director Michael J. Purcell purchased $50,000 of company stock at $0.04 per share, a price significantly above the current market value, as part of a broader insider buying trend.

check_boxKey Events

• Director's Significant Stock Purchase

  Director Michael J. Purcell acquired $50,000 worth of common stock, representing over 10% of the company's market capitalization.

• Purchase at Substantial Premium

  Shares were bought at $0.04 each, approximately 30 times higher than the current market price of $0.0013.

• Part of Broader Insider Buying

  This purchase is one of several recent insider transactions, including the Interim CEO and Executive Chairman, all buying at the $0.04 price, likely linked to a recent private placement.

auto_awesomeAnalysis

This Form 4 filing reveals Director Michael J. Purcell's significant open-market purchase of $50,000 worth of Hepion Pharmaceuticals common stock. This transaction is particularly notable as it represents over 10% of the company's current market capitalization and was executed at a price of $0.04 per share, which is approximately 30 times higher than the current stock price of $0.0013. This purchase is part of a cluster of insider buying, including the Interim CEO and Executive Chairman, all transacting at the same $0.04 price, likely related to the recent $700,000 private placement announced on April 22, 2026. Such a substantial investment at a significant premium to the market price signals strong conviction from the board regarding the company's future prospects, despite recent stock performance.